Why do chatbots work? A randomized controlled trial to test the effect of behaviorally-informed chatbot functionalities on vaccine uptake

Submission date	Recruitment status No longer recruiting	[X] Prospectively registered		
10/06/2024		[X] Protocol		
Registration date	Overall study status Completed Condition category Infections and Infestations	[X] Statistical analysis plan		
13/06/2024		Results		
Last Edited		Individual participant data		
08/08/2024		Record updated in last year		

Plain English summary of protocol

Background and study aims

Despite overwhelming medical evidence on the protection offered by second, third and fourth COVID-19 vaccine doses, uptake of these doses remain low despite available supply. Similarly, despite evidence of the protection offered by the influenza (flu) vaccine, vaccine uptake remains low despite available supply. There is particularly high risk for people living with risk factors and people older than 65 years.

This study will design and implement an intervention to increase immunization behaviors amongst the general adult population eligible for influenza vaccines and COVID-19 booster doses in Tucuman, Argentina. It will create a WhatsApp chatbot with personalized messages informing participants they are eligible for the next dose, sharing practical information on where and when to get vaccinated, providing planning prompts and enabling them to set their own reminders to get their next dose of the COVID-19 or flu vaccine on a convenient date. This is a large-scale randomized controlled trial to assess the impact of behaviourally-informed chatbot features on COVID-19 and influenza vaccination as measured through Ministry of Health data.

Who can participate?

Residents of Tucuman aged 18 years or older who are eligible for either their next COVID-19 dose or a government-subsidized flu vaccine, and have an active WhatsApp account. COVID-19 vaccine eligibility includes individuals aged 18-49 years who have not received a dose in the last 12 months and those aged 50+ years or with health risk factors who have not received a dose in the last 6 months. Flu vaccine eligibility includes individuals aged 65+ years, those with health risk factors, health and security personnel, and those with a prior prescription for the flu vaccine. Additionally, participants have a unique, validly formatted mobile phone in the Tucumán Ministry of Health databases.

What does the study involve?

Participants are randomly assigned at the individual level to one of four groups in equal

proportions. Three of these groups receive a WhatsApp chatbot with different added functionalities, while a control group receives no messages. Participants in treatment 1 (T1) are sent a Whatsapp chatbot with a personalized Whatsapp message reminding them of their eligibility to get their next COVID-19 and/or flu vaccine, a prompt to plan a day and time to receive their vaccine(s), and the option to set a reminder message for a day before their selected vaccination day. Participants treatment 2 (T2) are sent a Whatsapp chatbot including all T1 functionalities plus the option to locate a health center to receive their vaccine and set a reminder that includes a Google Maps link from their current location to the selected center, in addition to T1 functionalities. Participants in treatment 3 are sent a Whatsapp chatbot including all T2 functionalities plus a video from a popular local artist encouraging vaccination. Across all treatments, participants can choose to reply to the chatbot's messages by interacting with a set menu of options. Those who choose not to interact with the chatbot do not receive any future messages. Participants in the control group do not receive any messages.

What are the possible benefits and risks of participating?

Participants may benefit from receiving personalized information about Influenza and COVID-19 vaccinations, aimed at promoting vaccination uptake. Major risks are not anticipated and the risk of lower vaccination outcomes was minimized by developing messages based on participatory research in Argentina.

Where is the study run from? Tucuman Ministry of Public Health (Argentina)

When is the study starting and how long is it expected to run for? January 2023 to September 2024

Who is funding the study? Vaccine Confidence Fund (USA)

Who is the main contact?

- 1. Adelaida Barrera, adelaida.barrera@bi.team
- 2. Sebastian Salomon-Ballada, sebastian.salomon.b@gmail.com

Contact information

Type(s)

Scientific, Principal Investigator

Contact name

Mr Sebastian Salomon-Ballada

Contact details

58 Victoria Embankment London United Kingdom EC4Y 0DS

sebastian.salomon@bi.team

Type(s)

Public, Principal Investigator

Contact name

Ms Adelaida Barrera

Contact details

58 Victoria Embankment London United Kingdom EC4Y 0DS

_

adelaida.barrera@bi.team

Type(s)

Principal Investigator

Contact name

Ms Rosario Ramos

Contact details

58 Victoria Embankment London United Kingdom EC4Y 0DS

_

rosario.ramos@bi.team

Type(s)

Principal Investigator

Contact name

Prof Ivan Budassi

Contact details

58 Victoria Embankment London United Kingdom EC4Y 0DS

_

ivanbudassi@gmail.com

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

Study information

Scientific Title

Why do chatbots work? A randomized controlled trial to test the effect of behaviorally-informed chatbot functionalities on vaccine uptake

Study objectives

The researchers are aiming to reject the following hypotheses that the difference between COVID-19 or flu vaccination rate over a 4-week period is statistically indistinguishable among:

Primary analysis:

H1: Participants who are sent a WhatsApp chatbot (T1-T2-T3) compared to those who are assigned to not receive any message

Secondary analysis:

H2: Participants who are sent a basic Whatsapp chatbot (T1) compared to those who are sent the same chatbot with an additional health center locator functionality (T2)

H3: Participants who are sent the T2 Whatsapp chatbot compared to those who are sent the same chatbot with an additional motivational video message featuring a popular figure (T3)

Robustness check:

H4: Participants who receive a basic Whatsapp chatbot (T1) compared to those who receive the same chatbot with an additional health center locator functionality (T2)

H5: Participants who receive the T2 Whatsapp chatbot compared to those who receive the same chatbot with an additional motivational video message featuring a popular figure (T3)

Ethics approval required

Ethics approval required

Ethics approval(s)

Approved 21/06/2023, Comité de Bioética, Hospital Universitario Fundación Favaloro (Bioethics committee, Favaloro Foundation University Hospital) (Av. Belgrano 1746, Buenos Aires, C1095, Argentina; +54 (0)11 4378 1229; comitedebioetica@ffavaloro.org), ref: CBE 962-22 Acta 172

Study design

Four-arm randomized controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Community

Study type(s)

Efficacy

Participant information sheet

Not available in web format, please use the contact details to request a participant information sheet

Health condition(s) or problem(s) studied

Promotion of COVID-19 and influenza vaccination in the general population

Interventions

The unit of randomisation is the individual as identified by an anonymized ID called 'patient ID'. Using a random number generator, the researchers assigned participants to one of four groups.

Participants in the control group won't be sent any messages. However, following the trial period, if any messages are found to be effective at encouraging vaccination, these individuals would be sent the most effective message.

Participants in treatment 1 will be sent a WhatsApp chatbot that:

- 1. Sends them a personalized WhatsApp message reminding them to get their next COVID-19 and/or flu vaccine
- 2. Prompts them to plan a day and time to receive their vaccine(s)
- 3. Reminds them a day before their selected vaccination day

Participants in treatment 2 will be sent a WhatsApp chatbot that includes all T2 functionalities and:

- 1. Helps them locate a health center where they can receive their vaccine(s)
- 2. Reminds them a day before their selected vaccination day, including a Google Maps link to get from their current location to the selected health center

Participants in treatment 3 will be sent a WhatsApp chatbot that includes all T3 functionalities and:

1. Sends a video by the popular band La Mosca from Argentina to complement the WhatsApp messages

Intervention Type

Behavioural

Primary outcome measure

'Next dose' COVID-19 or Flu Vaccination Rate, a binary indicator of whether the individual receives a vaccination within 4 weeks of the assigned data for the sending of the initial message (COVID-19 or flu) (1 if they do, 0 if not)

Secondary outcome measures

Effect of chatbot functionalities on 'Next dose' COVID-19 or flu vaccination rate, a binary indicator of whether the individual receives a vaccination within 4 weeks of the assigned data for the sending of the initial message (COVID-19 or flu) (1 if they do, 0 if not)

Overall study start date

23/01/2023

Completion date

30/09/2024

Eligibility

Key inclusion criteria

Current participant inclusion criteria as of 05/08/2024:

- 1. Is 18 years of age or older
- 2. Is a resident of the province of Tucuman
- 3. Is eligible to receive their next COVID-19 dose or a government-subsidized flu vaccine:
- 3.1. COVID-19 vaccine eligibility criteria:
- 3.1.1. Individual is between 18 and 49 years old and is eligible for their booster shot based on time since last dose, i.e. has not had a COVID-19 shot in the last 12 months
- 3.1.2. Individual is 50 years old or older or has health risk factors and has not had a COVID-19 shot in the last 6 months
- 3.2. Government-subsidized flu vaccine eligibility criteria:
- 3.2.1. Citizens who are 65 years old or above
- 3.2.2. Citizens with a health risk factor
- 3.2.3. Health/security personnel
- 3.2.4. Citizens who had a medical prescription to receive the flu vaccine before
- 4. Mobile number is unique to one individual within the database
- 5. Mobile number has a valid format in Argentina
- 6. The user has an active WhatsApp account

Previous participant inclusion criteria:

- 1. Is 18 years of age or older
- 2. Is a resident of the province of Tucuman
- 3. Is eligible to receive their next COVID-19 dose or a government-subsidized flu vaccine:
- 3.1. COVID-19 vaccine eligibility criteria:
- 3.1.1. Individual is between 18 and 49 years old and is eligible for their booster shot based on time since last dose, i.e. has not had a COVID-19 shot in the last 12 months
- 3.1.2. Individual is 50 years old or older or has health risk factors and has not had a COVID-19 shot in the last 6 months
- 3.2. Government-subsidized flu vaccine eligibility criteria:
- 3.2.1. Citizens who are 65 years old or above
- 3.2.2. Citizens with a health risk factor
- 3.2.3. Health/security personnel
- 3.2.4. Citizens who had a medical prescription to receive the flu vaccine before
- 4. Mobile number is unique to one individual within the database
- 5. Mobile number has a valid format in Argentina

Participant type(s)

Population

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

Key exclusion criteria

Does not meet the inclusion criteria

Date of first enrolment

07/08/2024

Date of final enrolment

30/08/2024

Locations

Countries of recruitment

Argentina

Study participating centre Ministerio de Salud Pública de Tucumán

25 de Mayo 90 San Miguel de Tucumán Argentina T4109ADB

Sponsor information

Organisation

The Behavioural Insights Team

Sponsor details

58 Victoria Embankment London England United Kingdom EC4Y 0DS

dpo@bi.team

Sponsor type

Research organisation

Website

https://www.bi.team/

ROR

https://ror.org/03mk5b468

Funder(s)

Funder type

Charity

Funder Name

Vaccine Confidence Fund

Alternative Name(s)

VCF

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United States of America

Results and Publications

Publication and dissemination plan

Planned publication in a peer-reviewed journal.

Intention to publish date

31/08/2025

Individual participant data (IPD) sharing plan

The researchers intend for anonymity-preserving data used in the analysis to be made publicly available in a publicly available repository. Further details regarding data sharing, including repository name and link, will be made available at a later date.

IPD sharing plan summary

Stored in publicly available repository, Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<u>Protocol file</u>		11/06/2024	13/06/2024	No	No
Statistical Analysis Plan	SAP included in protocol	11/06/2024	08/08/2024	No	No